INmune Bio (INMB) said Wednesday it has entered into deal to use Vivo, a generative artificial intelligence-powered control tower produced by OmniScience, in undertaking its global phase 2 Alzheimer's disease clinical trial.
Vivo is designed specifically for centralizing and analyzing vast clinical data in real time, according to INmune. With insights becoming immediately available using Vivo, the company expects enhanced decision-making in the clinical trial.
Terms of the partnership weren't disclosed.
Shares of INmune Bio were more than 3% lower in recent trading.
Price: 5.00, Change: -0.17, Percent Change: -3.29
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.